The economic impact of factor VIII inhibitors in patients with haemophilia

Rhonda L. Bohn(Brigham and Women's Hospital), Jerry Avorn(Brigham and Women's Hospital), Kathleen Putnam(Brigham and Women's Hospital), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Bruce M. Ewenstein(CSL (United States)), Helen Mogun(Brigham and Women's Hospital)
Haemophilia
January 1, 2004
10.1046/j.1365-2516.2003.00849.x
Cited by 55

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587